// App-Quantinova.ai

SAT0431 : PROPORTIONS OF PATIENTS ACHIEVING A MINIMAL DISEASE ACTIVITY STATE UPON TREATMENT WITH TILDRAKIZUMAB IN A PSORIATIC ARTHRITIS PHASE 2B STUDY

Researchers

Presenter

  • P. Nash

Principal Investigators

  • M. E. Luggen

  • L. Espinoza

  • F. J. Garca Fructuoso

  • R. C. Chou

  • A. M. Mendelsohn

  • S. Rozzo

  • I. Mcinnes

Medical Centers

  • School of Medicine, Griffith University, QLD, Australia, Brisbane, Australia

  • Cincinnati Rheumatic Disease Study Group, Inc, and Univ of Cincinnati College of Medicine, Cincinnati, United States of America

  • LSU Health Sciences Center, New Orleans, United States

  • Hospital CIMA, Barcelona, Spain

  • University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, United States of America

  • Sun Pharmaceutical Industries, Inc., Medical Affairs, Princeton, United States of America

  • University of Glasgow, Glasgow, United Kingdom

Locations

  • Australia

  • United States

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • Malondialdehyde

Drug/Treatment

  • Tildrakizumab

  • MK-3222

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • NCT02980692

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved